In vitro and in vivo testing methods of epigenomic endpoints for evaluating endocrine disruptors

John M. Greally, Miriam N. Jacobs

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Epigenetic modulations underlie critical developmental processes and contribute to determining adult phenotype. Alterations to the phenotype, due to exposure to environmental insults during sensitive periods of development, are mediated through alterations in epigenetic programming in affected tissues. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review evaluates the potential role of chemical-induced epigenetic modifications to endocrine signaling pathways during sensitive windows of exposure as a mechanism of endocrine disruption, along with the examination of potential methods for assessing such disruption. Potential targets of disruption along putative adverse outcome pathways associated with the signaling pathways are identified, along with assays that show promise in evaluating the target in a screening and testing program such that in vitro methods are used where possible, and animal experiments only where in vitro methods are not available. Monitoring such epigenetic marks in response to toxicant exposure may in future provide a valuable tool for predicting adverse outcomes, but a more robust basis for Test Guideline recommendations is still needed. Although there is evidence to suggest that epigenomic dysregulation might mediate effects of exposures to endocrine disruptors, it is uncertain as to whether these changes are truly predictive of adverse outcome(s). Adverse effects observed in the OECD transgenerational assays could be used to inform future tests specifically designed to investigate the epigenetic mechanism of action. Follow-up studies should include both an epigenetic as well as a genomic component to differentiate between the contributions of potentially compensatory mechanisms.

Original languageEnglish (US)
Pages (from-to)445-471
Number of pages27
JournalAltex
Volume30
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Endocrine Disruptors
Epigenomics
Phenotype
Environmental Exposure
In Vitro Techniques
Guidelines

Keywords

  • Endocrine active substances
  • Endocrine disruptors
  • Epigenome
  • Regulatory methods
  • Toxicity testing

ASJC Scopus subject areas

  • Medical Laboratory Technology
  • Pharmacology

Cite this

In vitro and in vivo testing methods of epigenomic endpoints for evaluating endocrine disruptors. / Greally, John M.; Jacobs, Miriam N.

In: Altex, Vol. 30, No. 4, 2013, p. 445-471.

Research output: Contribution to journalArticle

@article{458cdf5ae2e04d13bef9162717424220,
title = "In vitro and in vivo testing methods of epigenomic endpoints for evaluating endocrine disruptors",
abstract = "Epigenetic modulations underlie critical developmental processes and contribute to determining adult phenotype. Alterations to the phenotype, due to exposure to environmental insults during sensitive periods of development, are mediated through alterations in epigenetic programming in affected tissues. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review evaluates the potential role of chemical-induced epigenetic modifications to endocrine signaling pathways during sensitive windows of exposure as a mechanism of endocrine disruption, along with the examination of potential methods for assessing such disruption. Potential targets of disruption along putative adverse outcome pathways associated with the signaling pathways are identified, along with assays that show promise in evaluating the target in a screening and testing program such that in vitro methods are used where possible, and animal experiments only where in vitro methods are not available. Monitoring such epigenetic marks in response to toxicant exposure may in future provide a valuable tool for predicting adverse outcomes, but a more robust basis for Test Guideline recommendations is still needed. Although there is evidence to suggest that epigenomic dysregulation might mediate effects of exposures to endocrine disruptors, it is uncertain as to whether these changes are truly predictive of adverse outcome(s). Adverse effects observed in the OECD transgenerational assays could be used to inform future tests specifically designed to investigate the epigenetic mechanism of action. Follow-up studies should include both an epigenetic as well as a genomic component to differentiate between the contributions of potentially compensatory mechanisms.",
keywords = "Endocrine active substances, Endocrine disruptors, Epigenome, Regulatory methods, Toxicity testing",
author = "Greally, {John M.} and Jacobs, {Miriam N.}",
year = "2013",
doi = "10.14573/altex.2013.4.445",
language = "English (US)",
volume = "30",
pages = "445--471",
journal = "Altex",
issn = "1868-596X",
publisher = "Elsevier GmbH",
number = "4",

}

TY - JOUR

T1 - In vitro and in vivo testing methods of epigenomic endpoints for evaluating endocrine disruptors

AU - Greally, John M.

AU - Jacobs, Miriam N.

PY - 2013

Y1 - 2013

N2 - Epigenetic modulations underlie critical developmental processes and contribute to determining adult phenotype. Alterations to the phenotype, due to exposure to environmental insults during sensitive periods of development, are mediated through alterations in epigenetic programming in affected tissues. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review evaluates the potential role of chemical-induced epigenetic modifications to endocrine signaling pathways during sensitive windows of exposure as a mechanism of endocrine disruption, along with the examination of potential methods for assessing such disruption. Potential targets of disruption along putative adverse outcome pathways associated with the signaling pathways are identified, along with assays that show promise in evaluating the target in a screening and testing program such that in vitro methods are used where possible, and animal experiments only where in vitro methods are not available. Monitoring such epigenetic marks in response to toxicant exposure may in future provide a valuable tool for predicting adverse outcomes, but a more robust basis for Test Guideline recommendations is still needed. Although there is evidence to suggest that epigenomic dysregulation might mediate effects of exposures to endocrine disruptors, it is uncertain as to whether these changes are truly predictive of adverse outcome(s). Adverse effects observed in the OECD transgenerational assays could be used to inform future tests specifically designed to investigate the epigenetic mechanism of action. Follow-up studies should include both an epigenetic as well as a genomic component to differentiate between the contributions of potentially compensatory mechanisms.

AB - Epigenetic modulations underlie critical developmental processes and contribute to determining adult phenotype. Alterations to the phenotype, due to exposure to environmental insults during sensitive periods of development, are mediated through alterations in epigenetic programming in affected tissues. Originally prepared for the Organisation of Economic Cooperation and Development (OECD), this detailed review evaluates the potential role of chemical-induced epigenetic modifications to endocrine signaling pathways during sensitive windows of exposure as a mechanism of endocrine disruption, along with the examination of potential methods for assessing such disruption. Potential targets of disruption along putative adverse outcome pathways associated with the signaling pathways are identified, along with assays that show promise in evaluating the target in a screening and testing program such that in vitro methods are used where possible, and animal experiments only where in vitro methods are not available. Monitoring such epigenetic marks in response to toxicant exposure may in future provide a valuable tool for predicting adverse outcomes, but a more robust basis for Test Guideline recommendations is still needed. Although there is evidence to suggest that epigenomic dysregulation might mediate effects of exposures to endocrine disruptors, it is uncertain as to whether these changes are truly predictive of adverse outcome(s). Adverse effects observed in the OECD transgenerational assays could be used to inform future tests specifically designed to investigate the epigenetic mechanism of action. Follow-up studies should include both an epigenetic as well as a genomic component to differentiate between the contributions of potentially compensatory mechanisms.

KW - Endocrine active substances

KW - Endocrine disruptors

KW - Epigenome

KW - Regulatory methods

KW - Toxicity testing

UR - http://www.scopus.com/inward/record.url?scp=84893099681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893099681&partnerID=8YFLogxK

U2 - 10.14573/altex.2013.4.445

DO - 10.14573/altex.2013.4.445

M3 - Article

VL - 30

SP - 445

EP - 471

JO - Altex

JF - Altex

SN - 1868-596X

IS - 4

ER -